SCHEMBL3833709

SCHEMBL3833709

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.44
GAA P10253 2/20 0.44
POLB P06746 1/20 0.44
MDM2 Q00987 1/20 0.44
RECQL P46063 1/20 0.44
MAPK1 P28482 1/20 0.43
MAT2A P31153 1/20 0.41
ACACB O00763 1/20 0.41
ACACA Q13085 1/20 0.41
LMNA P02545 1/20 0.41
MAPK8 P45983 1/20 0.41
MAPK9 P45984 1/20 0.41
KDM4E B2RXH2 2/20 0.40
ADORA2B P29275 1/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3837424 0.90 MAPT (0.48) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL16474394 0.85 MAPT (0.54) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2960195 0.83 ALDH1A1 (0.56) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1265759 0.83 MAPT (0.52) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL5650136 0.82 MAPT (0.51) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3836922 0.82 CASP3 (0.47) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2783455 0.81 MAPT (0.50) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3837237 0.81 MAPT (0.46) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL5648517 0.80 ALDH1A1 (0.50) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3835945 0.80 MAPT (0.49) MAPTMEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592455-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA S.A. (BE) 2009-09-22 US claimed
US-20060025428-A1 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA S.A. (BE) 2006-02-02 US claimed
US-7592455-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA S.A. (BE) 2009-09-22 US disclosed
US-20060025428-A1 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA S.A. (BE) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025428-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K6 MAPT 1954/4885MEN1 4813/4885KMT2A 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.